Protocol Ledger

NCT07236099 · Phase II · RECRUITING

Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis

Interventional Phase II clinical trial protocol NCT07236099 sponsored by Beijing InnoCare Pharma Tech Co in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-11-27 Enrollment: 135 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07236099
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)135 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07236099
Protocol FieldVerified Registry Value
NCT IdentifierNCT07236099
Consolidated Lead SponsorBeijing InnoCare Pharma Tech Co
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment135 participants (ESTIMATED)
Registered Start Date2025-11-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07236099
Hospital Research SiteLocationSite Profile
Center for Dermatology Clinical Research, Inc.Fremont, CAOpen Hospital Dossier ->
Dawes Fretzin Clinical Research Group, LLCIndianapolis, INOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI